[1] Wierstra I, Alves J. FOXM1, a typical proliferationassociated transcription factor[J]. Biol Chem, 2007, 388(12): 1257-1274.
[2] Xia L, Mo P, Huang W, et al. The TNFα/ROS/HIF1induced upregulation of FoxMⅠ expression promotes HCC proliferation and resistance to apoptosis[J]. Carcinogenesis, 2012, 33(11): 2250-2259.
[3] Yang C, Chen H, Yu L, et al. Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer[J]. Cancer Gene Ther, 2013, 20(2): 117-124.
[4] Priller M, Pschl J, Abro L, et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients[J]. Clin Cancer Res, 2011, 17(21): 6791-6801.
[5] Huang C, Qiu Z, Wang L, et al. A novel FoxM1caveolin signaling pathway promotes pancreatic cancer invasion and metastasis[J]. Cancer Res, 2012, 72(3): 655-665.
[6] Liu Y, Hock JM, Van Beneden RJ, et al. Aberrant overexpression of FOXM1 transcription factor plays a critical role in lung carcinogenesis induced by low doses of arsenic[J]. Mol Carcinog, 2012, In press.
[7] Yang DK, Son CH, Lee SK, et al. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance[J]. Hum Pathol, 2009, 40(4): 464-470.
[8] Gialmanidis IP, Bravou V, Amanetopoulou SG, et al. Overexpression of hedgehog pathway molecules and FOXM1 in nonsmall cell lung carcinomas[J]. Lung Cancer, 2009, 66(1): 64-74.
[9] Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family[J]. Prog Cell Cycle Res, 2000, 4: 107-114.
[10] Chen YJ, DominguezBrauer C, Wang Z, et al. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclinCDK1[J]. J Biol Chem, 2009, 284(44): 30695-30707.
[11] Bellelli R, Castellone MD, GarciaRostan G, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma[J]. Endocr Relat Cancer, 2012, 19(5): 695-710.
[12] Ackermann Misfeldt A, Costa RH, Gannon M. Betacell proliferation, but not neogenesis, following 60% partial pancreatectomy is impaired in the absence of FoxM1[J]. Diabetes, 2008, 57(11): 3069-3077.
[13] Petrovic V, Costa RH, Lau LF, et al. FoxM1 regulates growth factorinduced expression of kinaseinteracting stathmin (KIS) to promote cell cycle progression[J]. J Biol Chem, 2008, 283(1): 453-460.
[14] Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells[J]. PLoS One, 2009, 4(5): e5592.
[15] Jonker HR, Ilin S, Grimm SK, et al. L11 domain rearrangement upon binding to RNA and thiostrepton studied by NMR spectroscopy[J]. Nucleic Acids Res, 2007, 35(2): 441-454.
[16] Kwok JM, Myatt SS, Marson CM, et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression[J]. Mol Cancer Ther, 2008, 7(7): 2022-2032.
[17] Kwok JM, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cell[J]. Mol Cancer Res, 2010, 8(1): 24-34.
[18] Krol J, Francis RE, Albergaria A, et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells[J]. Mol Cancer Ther, 2007, 6(12 Pt 1): 3169-3179.
[19] Hui RC, Francis RE, Guest SK, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells[J]. Mol Cancer Ther, 2008, 7(3): 670-678.
[20] McGovern UB, Francis RE, Peck B, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer[J]. Mol Cancer Ther, 2009, 8(3): 582-591. |